Search | Clinical Trials Finder

Conditions: Glaucoma, Ocular Hypertension
Interventions: brimonidine 0.1%, Apraclonidine 0.5%; Drug
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Presbyopia, Refractive Errors, Eye Diseases
Interventions: Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle proprietary ophthalmic solution; Drug
Lead sponsor: LENZ Therapeutics, Inc; Other
Eligibility: 45 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 5
States / cities: Chandler, Arizona • Glendale, California • Andover, Massachusetts + 2 more

Conditions: Glaucoma
Interventions: Dorzolamide 2%-timolol 0.5%, Brimonidine 0.2%-0.5% timolol 0.5; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 40 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Eye Diseases, Presbyopia, Refractive Errors, Brimonidine Tartrate, Aceclidine, Ophthalmic Solutions
Interventions: Aceclidine + Brimonidine, Aceclidine; Drug
Lead sponsor: LENZ Therapeutics, Inc; Other
Eligibility: 45 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Intraoperative Floppy Iris Syndrome
Interventions: Brimonidine Tartrate; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 100 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Glaucoma, Open Angle
Interventions: brimonidine, timolol; Drug
Lead sponsor: Chicago Center for Vision Research; Other
Eligibility: 30 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 12
States / cities: Little Rock, Arkansas • Gainesville, Florida • Palm Beach Gardens, Florida + 7 more

Conditions: Ocular Redness
Interventions: Placebo, Brimonidine tartrate 0.025%; Drug
Lead sponsor: Eye Therapies, LLC; Industry
Eligibility: 40 Years and older
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Erythema, Rosacea
Interventions: CD07805/47 gel 0.5%/CD07805/47 Vehicle, azelaic acid gel 15%; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 4
States / cities: Evansville, Indiana • Louisville, Kentucky • Austin, Texas + 1 more

Conditions: Dry Eye
Interventions: Brimonidine Tartrate, Placebos; Drug
Lead sponsor: Ocugen; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 16
States / cities: Newport Beach, California • Rancho Cordova, California • Pompano Beach, Florida + 11 more

Conditions: Rosacea
Interventions: Brimonidine, placebo; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 16
States / cities: Hot Springs, Arkansas • Long Beach, California • Miami, Florida + 12 more

Conditions: Ocular Redness
Interventions: BTOS-HA, Lumify®; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 11
States / cities: Glendale, California • Newport Beach, California • Northbrook, Illinois + 8 more

Conditions: Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs, Droopy Eyelid, Ptosis, Glaucoma, Primary Open Angle
Interventions: brimonidine tartrate ophthalmic solution 0.025%, sterile balanced saline solution; Drug · Other
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Dermatochalasis of Eyelid, Ptosis, Eyelid, Ectropion, Entropion
Interventions: Brimonidine Topical; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Healthy
Interventions: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P); Drug
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Allergic Conjunctivitis
Interventions: Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 5 Years and older
Enrollment: 512 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 7
States / cities: Chandler, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 4 more

Conditions: Rosacea
Interventions: Brimonidine 0.33% gel (Br), CD07805/47 (Br) placebo gel, Ivermectin 1% cream (IVM), CD5024 (IVM) placebo cream; Drug · Other
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: Fort Smith, Arkansas • Rogers, Arkansas • Sacramento, California + 4 more

Conditions: Glaucoma, Open-Angle, Glaucoma; Drugs
Interventions: dorzolamide/timolol; Drug
Lead sponsor: CT Glaucoma Associates; Other
Eligibility: 25 Years to 90 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Norwalk, Connecticut

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Intraocular Pressure
Interventions: Alphagan, Phenylephrine, Tropicamide; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 50 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Glaucoma
Interventions: brimonidine 0.15%; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 35 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: No Intervention; Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Wheaton, Illinois

Conditions: Rhegmatogenous Macula-off Retinal Detachment
Interventions: 400 ug Brimonidine Implant, 200 ug Brimonidine Implant, Sham (no implant); Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Abilene, Texas

Conditions: Glaucoma
Interventions: Brimonidine Tartrate Ophthalmic 0.025%; Drug
Lead sponsor: Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Cataract
Interventions: Brimonidine Purite; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 4
States / cities: Indianapolis, Indiana

Search by objective public record fields.

Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty

Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia

Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)

Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

Pupil Dilation for Treatment of IFIS

Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma

Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects

Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea

Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)

Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness

The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients

Brimonidine for Intraoperative Hemostasis

Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients

Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma

A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients